查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046648

糖尿病足潰瘍生物製劑市場－全球產業規模、佔有率、趨勢、機會、預測：按適應症、最終用戶、地區和競爭對手分類，2021-2031年

Diabetic Foot Ulcer Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球糖尿病足潰瘍生物製劑市場預計將從 2025 年的 21.8 億美元大幅成長至 2031 年的 34.5 億美元，複合年成長率為 7.95%。

這些先進的創傷護理療法，包括生長因子、生物工程皮膚替代物和幹細胞，均源自天然生物材料，並專門用於促進慢性下肢損傷的癒合。推動市場成長的關鍵因素包括全球糖尿病盛行率的上升（這與難癒合傷口的增加直接相關）以及人口老化導致的血管併發症增加。此外，與傳統敷料相比，保肢療法的臨床需求日益成長，加速了這些創新再生醫學解決方案的應用。儘管全球糖尿病患者群體不斷擴大——預計到2024年，全球將有約5.89億成年人患有糖尿病，且患潰瘍併發症的風險很高，需要生物干預——但這些治療方法的高昂成本仍然是市場擴張的一大障礙。高昂的價格往往導致嚴格的報銷標準和有限的保險覆蓋範圍，從而限制了患者獲得這些重要治療的機會，尤其是在對成本高度敏感的醫療環境中。

市場概覽
預測期 2027-2031
市場規模：2025年 21.8億美元
市場規模：2031年 34.5億美元
複合年成長率：2026-2031年 7.95%
成長最快的細分市場 醫院
最大的市場 北美洲

市場促進因素

全球糖尿病足潰瘍生物製劑市場的主要驅動力是糖尿病在全球範圍內的盛行率不斷上升以及由此導致的足部併發症的增加。隨著全球糖尿病發生率的上升，出現難以癒合的慢性下肢病變的患者數量顯著增加，凸顯了除傳統敷料外，對先進再生醫學的迫切臨床需求。病患負擔的加重直接轉化為對有效傷口管理解決方案的持續需求。史密斯醫療（Smith & Nephew）的先進傷口管理業務部門報告稱，截至2024年2月，其基本銷售額成長率為6.4%，表明在這一高發病率患者群體中，對有效治療性介入的需求依然存在。同時，先進生物製劑作為傳統創傷護理方法的替代方案的日益普及，也顯著推動了市場成長。由於生物工程皮膚替代物和羊膜組織同種異體移植在促進難治性潰瘍癒合方面具有卓越的療效，醫療機構正擴大將其納入治療方案。這項轉變主要得益於市場領導者的強勁表現。 Organogenesis Holdings Inc. 於 2024 年 11 月公佈，其先進創傷護理產品的淨銷售額達到 1.08 億美元，年增 7%。此外，MiMedx Group, Inc. 於 2024 年 10 月公佈的淨銷售額為 8,400 萬美元，凸顯了這些再生醫學技術在業界顯著的商業性規模和快速普及，預示著市場將呈現強勁的成長勢頭。

市場挑戰

用於治療糖尿病足潰瘍的生物製藥價格高昂，嚴重阻礙了保險報銷和患者就醫，嚴重限制了市場成長。這些先進治療方法需要複雜的生物工程和生產流程，這也是其價格高的原因之一。如此高成本往往超出標準保險的報銷限額，迫使公共和私人保險公司實施嚴格的用藥控制策略。這些策略通常要求患者在核准生物製藥治療前，必須先對價格較低的傳統治療方法無效，這不僅延誤了必要的治療，也阻​​礙了醫療服務提供者開立這些有效但高成本的藥物。醫療保健系統面臨的巨大經濟負擔進一步加劇了這個問題，迫使保險公司優先考慮成本控制而非臨床療效。例如，美國糖尿病協會預測，到2025年，美國糖尿病相關醫療保健的年度總支出將達到約4,130億美元。如此巨大的經濟壓力迫使保險公司採取嚴格的報銷標準，導致高品質的創傷護理產品經常被拒絕。因此，儘管生物製藥療法具有明顯的臨床益處，但在全球醫療保健環境日益注重成本效益的背景下，其經濟永續性的缺失嚴重限制了生物療法的廣泛應用。

市場趨勢

市場格局正經歷重大變革，這主要得益於魚皮來源的無細胞真皮基質日益廣泛的應用，而其獨特的結構特性和抗發炎功效更是推動了這一趨勢。與哺乳動物移植不同，這些魚皮來源的異質骨移植具有富含Omega-3脂肪酸且無病毒感染風險等優勢。這使得其加工過程更加溫和，同時又能保持天然的多孔結構，而這對於糖尿病足潰瘍的有效細胞浸潤和血管生成至關重要。該技術的快速市場滲透表明，臨床醫生越來越青睞這種永續且有效的替代傳統生物材料的方案。 Coloplast A/S旗下Kelesys業務部門2025年11月的20%銷售成長也印證了這一趨勢，證實了市場對魚皮再生醫學解決方案的強勁需求。同時，隨著醫療專業人員擴大採用高活性配方來調節慢性傷口的微環境，基於胜肽的創傷治療療法的重要性也日益凸顯。這些療法通常源自水解膠原蛋白，能夠釋放生物活性胜肽，有效刺激肉芽組織形成和清創，從而作為標準減負和清創方案的輔助手段，用於治療難癒合的病變。市場向高反應性和生物活性藥物的顯著轉變體現在關鍵細分領域公司的強勁業績上，例如，Sanara MedTech公司2025年第三季淨銷售額達2,630萬美元，較去年同期成長22%。這主要得益於該公司軟組織修復和生物活性創傷護理產品組合的銷售加速成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：糖尿病足潰瘍生物製劑的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 適應症（神經缺血性潰瘍、神經病變糖尿病足潰瘍、缺血性糖尿病足潰瘍）
    • 依最終使用者（醫院、診所、門診手術中心、長期照護機構等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美糖尿病足潰瘍生物製劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲糖尿病足潰瘍生物製劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區糖尿病足潰瘍生物製劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲糖尿病足潰瘍生物製劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲糖尿病足潰瘍生物製劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球糖尿病足潰瘍生物製劑市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Organogenesis Holdings Inc.
  • Tissue Regenix Group plc
  • BioTissue Holdings Inc.
  • Integra LifeSciences Holdings Corp.
  • MIMEDX Group, Inc.
  • Convatec Inc.
  • Coloplast Group
  • Smith & Nephew plc
  • LifeNet Health
  • GUNZE Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 28114

The Global Diabetic Foot Ulcer (DFU) Biologics Market is projected to expand significantly, increasing from USD 2.18 Billion in 2025 to USD 3.45 Billion by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 7.95%. These advanced wound care therapeutics, including growth factors, bioengineered skin substitutes, and stem cells, are derived from natural biological sources and are specifically designed to accelerate the healing of chronic lower limb lesions. Key factors fueling this market growth include the escalating worldwide incidence of diabetes mellitus, which directly contributes to the rise of difficult-to-heal wounds, alongside an aging population more susceptible to vascular complications. Furthermore, a growing clinical need for limb salvage therapies, offering superior effectiveness compared to traditional dressings, is accelerating the adoption of these innovative regenerative solutions.Despite the expanding global patient base, with approximately 589 million adults living with diabetes in 2024 who are prone to ulcerative complications requiring biologic interventions, a notable obstacle to market expansion remains the substantial cost associated with these therapies. These high pricing structures frequently lead to rigorous reimbursement criteria and restricted insurance coverage, consequently limiting patient access to these crucial treatments, especially within cost-sensitive healthcare environments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.18 Billion
Market Size 2031USD 3.45 Billion
CAGR 2026-20317.95%
Fastest Growing SegmentHospitals
Largest MarketNorth America

Market Driver

The primary catalyst propelling the Global Diabetic Foot Ulcer Biologics Market is the escalating global prevalence of diabetes mellitus and its associated foot complications. As diabetes rates climb worldwide, there has been a significant surge in patients developing chronic, challenging-to-heal lower limb lesions, underscoring a critical clinical demand for advanced regenerative therapies beyond conventional dressings. This increasing patient burden directly translates into sustained demand for effective wound management solutions, as evidenced by Smith+Nephew's Advanced Wound Management business unit reporting a 6.4% underlying revenue growth in February 2024, highlighting the persistent need for effective interventions in this high-morbidity patient population.Simultaneously, the increasing adoption of advanced biologics over traditional wound care methods is significantly fueling market expansion. Healthcare providers are progressively incorporating bioengineered skin substitutes and amniotic tissue allografts into treatment protocols, driven by their superior efficacy in promoting the closure of refractory ulcers. This shift is corroborated by strong financial performances from market leaders, with Organogenesis Holdings Inc. reporting a 7% year-over-year increase in net revenue for its Advanced Wound Care products to $108 million in November 2024. Furthermore, MiMedx Group, Inc.'s reported net sales of $84 million in October 2024 confirm the substantial commercial scale and rapid uptake of these regenerative technologies within the industry, indicating a robust market trajectory.

Market Challenge

The substantial cost associated with diabetic foot ulcer biologics significantly impedes market growth by creating considerable obstacles to both reimbursement and patient access. These advanced therapies necessitate complex bioengineering and manufacturing processes, which contribute to their premium pricing. Such elevated costs often exceed standard insurance coverage limits, prompting public and private payers to implement stringent utilization management strategies. These strategies frequently require patients to first fail less expensive conventional treatments before approving biologic interventions, which not only delays essential care but also discourages healthcare providers from prescribing these effective yet costly options.This issue is further compounded by the immense financial strain on healthcare systems, which often compels payers to prioritize cost containment over advanced clinical efficacy. For instance, the American Diabetes Association projected the total annual economic burden of diabetes-related care in the United States alone to reach approximately $413 billion by 2025. This significant fiscal pressure forces insurers to enforce rigorous reimbursement criteria, leading to frequent denial rates for premium wound care products. Consequently, despite their clear clinical benefits, the widespread adoption of biologic therapies is severely constrained by their economic unsustainability in a global healthcare environment increasingly focused on cost-efficiency.

Market Trends

The market landscape is undergoing a significant transformation due to the increasing adoption of fish-skin acellular dermal matrices, driven by their distinct structural and anti-inflammatory attributes. Unlike mammalian-derived grafts, these piscine xenografts offer advantages such as being rich in Omega-3 fatty acids and posing no risk of viral transmission, which allows for gentler processing that maintains the natural porous architecture crucial for effective cell ingrowth and vascularization in diabetic foot ulcers. The swift commercial uptake of this technology highlights its growing favor among clinicians who are seeking sustainable and effective alternatives to conventional biologics, a trend underscored by Coloplast A/S's Kerecis business unit reporting a 20% revenue growth in November 2025, confirming robust demand for these fish-skin-based regenerative solutions.Concurrently, there is a growing prominence of peptide-based wound healing therapeutics, as healthcare providers increasingly employ advanced bioactive formulations to modulate the chronic wound microenvironment. These therapeutics, frequently derived from hydrolyzed collagen, release bioactive peptides that actively stimulate granulation tissue formation and re-epithelialization, thereby serving as a versatile adjunct to standard offloading and debridement protocols for hard-to-heal lesions. This discernible market shift towards responsive, biologically active agents is reflected in the strong performance of key segment players, with Sanara MedTech reporting a 22% year-over-year increase in net revenue to $26.3 million in the third quarter of 2025, largely propelled by accelerated sales within its soft tissue repair and bioactive wound care portfolio.

Key Market Players

  • Organogenesis Holdings Inc.
  • Tissue Regenix Group plc
  • BioTissue Holdings Inc.
  • Integra LifeSciences Holdings Corp.
  • MIMEDX Group, Inc.
  • Convatec Inc.
  • Coloplast Group
  • Smith & Nephew plc
  • LifeNet Health
  • GUNZE Limited

Report Scope

In this report, the Global Diabetic Foot Ulcer Biologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Foot Ulcer Biologics Market, By Indication

  • Neuro-ischemic Ulcers
  • Neuropathic Diabetic Foot Ulcer
  • Ischemic Diabetic Foot Ulcer

Diabetic Foot Ulcer Biologics Market, By End User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Long-Term Care Settings
  • Others

Diabetic Foot Ulcer Biologics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Foot Ulcer Biologics Market.

Available Customizations:

Global Diabetic Foot Ulcer Biologics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Diabetic Foot Ulcer Biologics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Neuro-ischemic Ulcers, Neuropathic Diabetic Foot Ulcer, Ischemic Diabetic Foot Ulcer)
    • 5.2.2. By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Long-Term Care Settings, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Diabetic Foot Ulcer Biologics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Diabetic Foot Ulcer Biologics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Diabetic Foot Ulcer Biologics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Diabetic Foot Ulcer Biologics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By End User

7. Europe Diabetic Foot Ulcer Biologics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Diabetic Foot Ulcer Biologics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By End User
    • 7.3.2. France Diabetic Foot Ulcer Biologics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Diabetic Foot Ulcer Biologics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Diabetic Foot Ulcer Biologics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Diabetic Foot Ulcer Biologics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By End User

8. Asia Pacific Diabetic Foot Ulcer Biologics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Diabetic Foot Ulcer Biologics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By End User
    • 8.3.2. India Diabetic Foot Ulcer Biologics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Diabetic Foot Ulcer Biologics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Diabetic Foot Ulcer Biologics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Diabetic Foot Ulcer Biologics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By End User

9. Middle East & Africa Diabetic Foot Ulcer Biologics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Diabetic Foot Ulcer Biologics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Diabetic Foot Ulcer Biologics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Diabetic Foot Ulcer Biologics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By End User

10. South America Diabetic Foot Ulcer Biologics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Diabetic Foot Ulcer Biologics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Diabetic Foot Ulcer Biologics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Diabetic Foot Ulcer Biologics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Diabetic Foot Ulcer Biologics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Organogenesis Holdings Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Tissue Regenix Group plc
  • 15.3. BioTissue Holdings Inc.
  • 15.4. Integra LifeSciences Holdings Corp.
  • 15.5. MIMEDX Group, Inc.
  • 15.6. Convatec Inc.
  • 15.7. Coloplast Group
  • 15.8. Smith & Nephew plc
  • 15.9. LifeNet Health
  • 15.10. GUNZE Limited

16. Strategic Recommendations

17. About Us & Disclaimer